1 |
Wang G, Xu J, Ma H, Mu Y, Xu W, Yan N, Liu W, Zheng D, Huang X, Li L. Phenolipid JE improves metabolic profile and inhibits gluconeogenesis via modulating AKT-mediated insulin signaling in STZ-induced diabetic mice. Pharmacol Res 2023;187:106569. [PMID: 36427798 DOI: 10.1016/j.phrs.2022.106569] [Reference Citation Analysis]
|
2 |
Seoane-Viaño I, Ong JJ, Basit AW, Goyanes A. To infinity and beyond: Strategies for fabricating medicines in outer space. Int J Pharm X 2022;4:100121. [PMID: 35782363 DOI: 10.1016/j.ijpx.2022.100121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
3 |
Hou L, Peng X, Wang R, Wang Y, Li H, Zhang H, Zhang Y, Zhang Z. Oral nano-formulation improves pancreatic islets dysfunction via lymphatic transport for antidiabetic treatment. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.12.014] [Reference Citation Analysis]
|
4 |
Bai J, Zhang H, Yang Z, Li P, Liu B, Li D, Liang S, Wang Q, Li Z, Zhang J, Chen S, Hou G, Li Y. On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide. J Control Release 2022;352:673-84. [PMID: 36374646 DOI: 10.1016/j.jconrel.2022.10.039] [Reference Citation Analysis]
|
5 |
Xie Y, Zhou Q, He Q, Wang X, Wang J. Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.008] [Reference Citation Analysis]
|